Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Graft Versus Host Disease (GVHD) Treatment Pipeline Review H2 2016

Friday, October 14, 2016 5:15
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Summary

‘Graft Versus Host Disease (GVHD) – Pipeline Review, H2 2016’, provides an overview of the Graft Versus Host Disease (GVHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (GVHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects.

Request a sample report @ https://www.wiseguyreports.com/sample-request/685908-graft-versus-host-disease-gvhd-pipeline-review-h2-2016

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (GVHD) 
- The report reviews pipeline therapeutics for Graft Versus Host Disease (GVHD) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Graft Versus Host Disease (GVHD) therapeutics and enlists all their major and minor projects 
- The report assesses Graft Versus Host Disease (GVHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (GVHD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Graft Versus Host Disease (GVHD) 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Graft Versus Host Disease (GVHD) pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @ https://www.wiseguyreports.com/enquiry/685908-graft-versus-host-disease-gvhd-pipeline-review-h2-2016

Key points in table of content

Table of Contents 2 
List of Tables 7 
List of Figures 9 
Introduction 10 
Global Markets Direct Report Coverage 10 
Graft Versus Host Disease (GVHD) Overview 11 
Therapeutics Development 12 
Pipeline Products for Graft Versus Host Disease (GVHD) – Overview 12 
Pipeline Products for Graft Versus Host Disease (GVHD) – Comparative Analysis 13 
Graft Versus Host Disease (GVHD) – Therapeutics under Development by Companies 14 
Graft Versus Host Disease (GVHD) – Therapeutics under Investigation by Universities/Institutes 19 
Graft Versus Host Disease (GVHD) – Pipeline Products Glance 21 
Late Stage Products 21 
Clinical Stage Products 22 
Early Stage Products 23 
Unknown Stage Products 24 
Graft Versus Host Disease (GVHD) – Products under Development by Companies 25 
Graft Versus Host Disease (GVHD) – Products under Investigation by Universities/Institutes 30 
Graft Versus Host Disease (GVHD) – Companies Involved in Therapeutics Development 31 
AbbVie Inc 31 
AbGenomics International, Inc. 32 
Actelion Ltd 33 
Alexion Pharmaceuticals Inc 34 
Amunix Operating Inc. 35 
Apceth GmbH & Co. KG 36 
arGEN-X BV 37 
Athersys, Inc. 38 
Bellicum Pharmaceuticals, Inc. 39 
Bio-Cancer Treatment International Limited 40 
Biogen Inc 41 
Bristol-Myers Squibb Company 42 
Cantex Pharmaceuticals, Inc. 43 
Capricor Therapeutics, Inc. 44 
Cell2B S.A. 45 
CellECT Bio, Inc. 46 
Cynata Therapeutics Limited 47 
Cytodyn Inc. 48 
Dompe Farmaceutici S.p.A. 49 
Dr. Falk Pharma GmbH 50 
Escape Therapeutics, Inc. 51 
F. Hoffmann-La Roche Ltd. 52 
Fate Therapeutics, Inc. 53 
Generon (Shanghai) Corporation Ltd. 54 
Gilead Sciences, Inc. 55 
GlaxoSmithKline Plc 56 
Idera Pharmaceuticals, Inc. 57 
ImmuNext, Inc. 58 
Immunomedics, Inc. 59 
Incyte Corporation 60 
Kadmon Corporation, LLC 61 
Kamada Ltd. 62 
Kiadis Pharma N.V. 63 
Kymab Limited 64 
Kyorin Pharmaceutical Co., Ltd. 65 
MacroGenics, Inc. 66 
Mallinckrodt Plc 67 
Medsenic 68 
Mesoblast Limited 69 
Millennium Pharmaceuticals Inc 70 
Neopharm Ltd. 71 
Nohla Therapeutics Inc. 72 
Novartis AG 73 
OncoImmune, Inc. 74 
OSE Immunotherapeutics 75 
Pharmicell Co., Ltd. 76 
REGiMMUNE Corporation 77 
Rigel Pharmaceuticals, Inc. 78 
Sarepta Therapeutics, Inc. 79 
Seattle Genetics, Inc. 80 
Seres Therapeutics, Inc. 81 
Sigmoid Pharma Limited 82 
Spherium Biomed S.L. 83 
Takeda Pharmaceutical Company Limited 84 
Targazyme, Inc. 85 
Therapix Biosciences Ltd. 86 
Tobira Therapeutics, Inc. 87 
Vault Pharma Inc. 88 
Xenikos B.V. 89 
ZIOPHARM Oncology, Inc. 90 
Graft Versus Host Disease (GVHD) – Therapeutics Assessment 91 
Assessment by Monotherapy Products 91 
Assessment by Combination Products 92 
Assessment by Target 93 
Assessment by Mechanism of Action 97 
Assessment by Route of Administration 101 
Assessment by Molecule Type 103 
Drug Profiles 105 
abatacept – Drug Profile 105 
AbGn-168H – Drug Profile 110 
AGS-499 – Drug Profile 112 
aldesleukin – Drug Profile 113 
Alecmestencel-L – Drug Profile 115 
alpha-1 proteinase inhibitor (human) – Drug Profile 116 
ALXN-1007 – Drug Profile 120 
AMX-342 – Drug Profile 122 
anti-thymocyte globulin (rabbit) – Drug Profile 123 
Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD – Drug Profile 125 
Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease – Drug Profile 126 
ARGX-115 – Drug Profile 127 
arsenic trioxide – Drug Profile 128 
ATIR-101 – Drug Profile 129 
BCT-200 – Drug Profile 133 
begelomab – Drug Profile 134 
Biologic to Activate IL-2 for Graft Versus Host Disease – Drug Profile 135 
Biologics for Graft Versus Host Disease – Drug Profile 136 
bortezomib – Drug Profile 137 
BPX-501 – Drug Profile 145 
brentuximab vedotin – Drug Profile 149 
budesonide – Drug Profile 173 
cannabidiol – Drug Profile 176 
CAP-2003 – Drug Profile 177 
CD-24Fc – Drug Profile 178 
Cell Therapy for Graft Versus Host Disease – Drug Profile 179 
Cell Therapy for Graft-Versus Host Disease – Drug Profile 180 
Cellgram for Graft Versus Host Disease – Drug Profile 181 
Cellular Immunotherapy for Acute Graft Versus Host Disease – Drug Profile 182 
Cellular Immunotherapy for Autoimmune Diseases and Transplantation – Drug Profile 183 
Cellular Immunotherapy for Graft Versus Host Disease – Drug Profile 185 
Cellular Immunotherapy for Graft Versus Host Disease – Drug Profile 186 
Cellular Immunotherapy for Graft Versus Host Disease – Drug Profile 187 
Cellular Immunotherapy for Graft Versus Host Disease – Drug Profile 188 
Cellular Immunotherapy for Graft Versus Host Disease – Drug Profile 189 
Cellular Immunotherapy for Graft Versus Host Disease – Drug Profile 190 
Cellular Immunotherapy for Graft Versus Host Disease – Drug Profile 191 
Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma – Drug Profile 192 
cenicriviroc mesylate – Drug Profile 193 
CRCBT-080004 – Drug Profile 200 
CX-01 – Drug Profile 201 
cyclosporine CR + cyclosporine IR – Drug Profile 203 
CYP-001 – Drug Profile 204 
entospletinib – Drug Profile 206 
F-652 – Drug Profile 208 
FR-104 – Drug Profile 209 
Ha-7 – Drug Profile 212 
ibrutinib – Drug Profile 213 
ImmuneSafe – Drug Profile 238 
ImmuStem – Drug Profile 239 
IMO-8400 – Drug Profile 240 
IT-603 – Drug Profile 246 
IT-901 – Drug Profile 247 
itacitinib adipate – Drug Profile 248 
KD-025 – Drug Profile 251 
KRP-203 – Drug Profile 255 
KY-1005 – Drug Profile 257 
MAX-16H5 – Drug Profile 258 
MesoStem – Drug Profile 259 
methoxsalen – Drug Profile 260 
MGD-010 – Drug Profile 262 
milatuzumab – Drug Profile 264 
Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases – Drug Profile 266 
natalizumab – Drug Profile 268 
nilotinib – Drug Profile 272 
obinutuzumab – Drug Profile 278 
OCU-300 – Drug Profile 285 
Oligonucleotide to Inhibit NFAT1 for GVHD – Drug Profile 286 
panobinostat – Drug Profile 287 
PF-05285401 – Drug Profile 295 
ponesimod – Drug Profile 305 
Preimplantation Factor – Drug Profile 307 
PRO-140 – Drug Profile 308 
ProTmune – Drug Profile 316 
R-348 – Drug Profile 318 
Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders – Drug Profile 320 
Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis – Drug Profile 321 
Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease – Drug Profile 322 
remestemcel-L – Drug Profile 323 
reparixin – Drug Profile 328 
RGI-2001 – Drug Profile 331 
RO-2959 – Drug Profile 333 
rovalpituzumab tesirine – Drug Profile 334 
ruxolitinib phosphate – Drug Profile 336 
S-Graft – Drug Profile 347 
SER-155 – Drug Profile 348 
Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis – Drug Profile 349 
Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis – Drug Profile 350 
Small Molecules to Inhibit SHIP1 for Oncology and Immunology – Drug Profile 351 
Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders – Drug Profile 352 
sonidegib phosphate – Drug Profile 353 
SP-12008 – Drug Profile 357 
SYGN-305 – Drug Profile 358 
Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease – Drug Profile 359 
T-Guard – Drug Profile 360 
TZ-101 – Drug Profile 362 
vedolizumab – Drug Profile 365 
VPI-101 – Drug Profile 369 
ZL-1101 – Drug Profile 370 
Graft Versus Host Disease (GVHD) – Dormant Projects 371 
Graft Versus Host Disease (GVHD) – Discontinued Products 376 
Graft Versus Host Disease (GVHD) – Product Development Milestones 377 
Featured News & Press Releases 377 
Appendix 388 
Methodology 388 
Coverage 388 
Secondary Research 388 
Primary Research 388 
Expert Panel Validation 388 
Contact Us 388 
Disclaimer 389

List of Tables 
Number of Products under Development for Graft Versus Host Disease (GVHD), H2 2016 19 
Number of Products under Development for Graft Versus Host Disease (GVHD) – Comparative Analysis, H2 2016 20 
Number of Products under Development by Companies, H2 2016 21 
Number of Products under Development by Companies, H2 2016 (Contd..1) 22 
Number of Products under Development by Companies, H2 2016 (Contd..2) 23 
Number of Products under Development by Companies, H2 2016 (Contd..3) 24 
Number of Products under Development by Companies, H2 2016 (Contd..4) 25 
Number of Products under Investigation by Universities/Institutes, H2 2016 27 
Comparative Analysis by Late Stage Development, H2 2016 28 
Comparative Analysis by Clinical Stage Development, H2 2016 29 
Comparative Analysis by Early Stage Development, H2 2016 30 
Comparative Analysis by Unknown Stage Development, H2 2016 31 
Products under Development by Companies, H2 2016 32 
Products under Development by Companies, H2 2016 (Contd..1) 33 
Products under Development by Companies, H2 2016 (Contd..2) 34 
Products under Development by Companies, H2 2016 (Contd..3) 35 
Products under Development by Companies, H2 2016 (Contd..4) 36 
Products under Investigation by Universities/Institutes, H2 2016 37 
Graft Versus Host Disease (GVHD) – Pipeline by AbbVie Inc, H2 2016 38 
Graft Versus Host Disease (GVHD) – Pipeline by AbGenomics International, Inc., H2 2016 39 
Graft Versus Host Disease (GVHD) – Pipeline by Actelion Ltd, H2 2016 40 
Graft Versus Host Disease (GVHD) – Pipeline by Alexion Pharmaceuticals Inc, H2 2016 41 
Graft Versus Host Disease (GVHD) – Pipeline by Amunix Operating Inc. , H2 2016 42 
Graft Versus Host Disease (GVHD) – Pipeline by Apceth GmbH & Co. KG, H2 2016 43 
Graft Versus Host Disease (GVHD) – Pipeline by arGEN-X BV, H2 2016 44 
Graft Versus Host Disease (GVHD) – Pipeline by Athersys, Inc., H2 2016 45 
Graft Versus Host Disease (GVHD) – Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 46 
Graft Versus Host Disease (GVHD) – Pipeline by Bio-Cancer Treatment International Limited, H2 2016 47 
Graft Versus Host Disease (GVHD) – Pipeline by Biogen Inc, H2 2016 48 
Graft Versus Host Disease (GVHD) – Pipeline by Bristol-Myers Squibb Company, H2 2016 49 
Graft Versus Host Disease (GVHD) – Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 50 
Graft Versus Host Disease (GVHD) – Pipeline by Capricor Therapeutics, Inc., H2 2016 51 
Graft Versus Host Disease (GVHD) – Pipeline by Cell2B S.A. , H2 2016 52 
Graft Versus Host Disease (GVHD) – Pipeline by CellECT Bio, Inc., H2 2016 53 
Graft Versus Host Disease (GVHD) – Pipeline by Cynata Therapeutics Limited, H2 2016 54 
Graft Versus Host Disease (GVHD) – Pipeline by Cytodyn Inc., H2 2016 55 
Graft Versus Host Disease (GVHD) – Pipeline by Dompe Farmaceutici S.p.A., H2 2016 56 
Graft Versus Host Disease (GVHD) – Pipeline by Dr. Falk Pharma GmbH, H2 2016 57 
Graft Versus Host Disease (GVHD) – Pipeline by Escape Therapeutics, Inc., H2 2016 58 
Graft Versus Host Disease (GVHD) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 59 
Graft Versus Host Disease (GVHD) – Pipeline by Fate Therapeutics, Inc., H2 2016 60 
Graft Versus Host Disease (GVHD) – Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 61 
Graft Versus Host Disease (GVHD) – Pipeline by Gilead Sciences, Inc., H2 2016 62 
Graft Versus Host Disease (GVHD) – Pipeline by GlaxoSmithKline Plc, H2 2016 63 
Graft Versus Host Disease (GVHD) – Pipeline by Idera Pharmaceuticals, Inc., H2 2016 64 
Graft Versus Host Disease (GVHD) – Pipeline by ImmuNext, Inc., H2 2016 65 
Graft Versus Host Disease (GVHD) – Pipeline by Immunomedics, Inc., H2 2016 66 
Graft Versus Host Disease (GVHD) – Pipeline by Incyte Corporation, H2 2016 67 
Graft Versus Host Disease (GVHD) – Pipeline by Kadmon Corporation, LLC, H2 2016 68 
Graft Versus Host Disease (GVHD) – Pipeline by Kamada Ltd., H2 2016 69 
Graft Versus Host Disease (GVHD) – Pipeline by Kiadis Pharma N.V., H2 2016 70 
Graft Versus Host Disease (GVHD) – Pipeline by Kymab Limited, H2 2016 71 
Graft Versus Host Disease (GVHD) – Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 72 
Graft Versus Host Disease (GVHD) – Pipeline by MacroGenics, Inc., H2 2016 73 
Graft Versus Host Disease (GVHD) – Pipeline by Mallinckrodt Plc, H2 2016 74 
Graft Versus Host Disease (GVHD) – Pipeline by Medsenic, H2 2016 75 
Graft Versus Host Disease (GVHD) – Pipeline by Mesoblast Limited, H2 2016 76 
Graft Versus Host Disease (GVHD) – Pipeline by Millennium Pharmaceuticals Inc, H2 2016 77 
Graft Versus Host Disease (GVHD) – Pipeline by Neopharm Ltd., H2 2016 78 
Graft Versus Host Disease (GVHD) – Pipeline by Nohla Therapeutics Inc., H2 2016 79 
Graft Versus Host Disease (GVHD) – Pipeline by Novartis AG, H2 2016 80 
Graft Versus Host Disease (GVHD) – Pipeline by OncoImmune, Inc., H2 2016 81 
Graft Versus Host Disease (GVHD) – Pipeline by OSE Immunotherapeutics, H2 2016 82 
Graft Versus Host Disease (GVHD) – Pipeline by Pharmicell Co., Ltd., H2 2016 83 
Graft Versus Host Disease (GVHD) – Pipeline by REGiMMUNE Corporation, H2 2016 84 
Graft Versus Host Disease (GVHD) – Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 85 
Graft Versus Host Disease (GVHD) – Pipeline by Sarepta Therapeutics, Inc., H2 2016 86 
Graft Versus Host Disease (GVHD) – Pipeline by Seattle Genetics, Inc., H2 2016 87 
Graft Versus Host Disease (GVHD) – Pipeline by Seres Therapeutics, Inc., H2 2016 88 
Graft Versus Host Disease (GVHD) – Pipeline by Sigmoid Pharma Limited, H2 2016 89 
Graft Versus Host Disease (GVHD) – Pipeline by Spherium Biomed S.L., H2 2016 90 
Graft Versus Host Disease (GVHD) – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 91 
Graft Versus Host Disease (GVHD) – Pipeline by Targazyme, Inc., H2 2016 92 
Graft Versus Host Disease (GVHD) – Pipeline by Therapix Biosciences Ltd., H2 2016 93 
Graft Versus Host Disease (GVHD) – Pipeline by Tobira Therapeutics, Inc., H2 2016 94 
Graft Versus Host Disease (GVHD) – Pipeline by Vault Pharma Inc., H2 2016 95 
Graft Versus Host Disease (GVHD) – Pipeline by Xenikos B.V., H2 2016 96 
Graft Versus Host Disease (GVHD) – Pipeline by ZIOPHARM Oncology, Inc., H2 2016 97 
Assessment by Monotherapy Products, H2 2016 98 
Assessment by Combination Products, H2 2016 99 
Number of Products by Stage and Target, H2 2016 101 
Number of Products by Stage and Mechanism of Action, H2 2016 105 
Number of Products by Stage and Route of Administration, H2 2016 109 
Number of Products by Stage and Molecule Type, H2 2016 111 
Graft Versus Host Disease (GVHD) – Dormant Projects, H2 2016 378 
Graft Versus Host Disease (GVHD) – Dormant Projects (Contd..1), H2 2016 379 
Graft Versus Host Disease (GVHD) – Dormant Projects (Contd..2), H2 2016 380 
Graft Versus Host Disease (GVHD) – Dormant Projects (Contd..3), H2 2016 381 
Graft Versus Host Disease (GVHD) – Dormant Projects (Contd..4), H2 2016 382 
Graft Versus Host Disease (GVHD) – Discontinued Products, H2 2016 383

Get this report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=685908

 

Contact US:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.